Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Taysha Gene Therapies EBIT Margin 2020-2023 | TSHA

Current and historical EBIT (Earnings Before Interest & Taxes) margin for Taysha Gene Therapies (TSHA) over the last 10 years. The current EBIT profit margin for Taysha Gene Therapies as of December 31, 2023 is .
  
Taysha Gene Therapies EBIT Margin Historical Data
Date TTM Revenue TTM EBIT EBIT Margin
2023-12-31 $0.02B $-0.07B -450.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.454B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $15.751B 5.69
Dr Reddy's Laboratories (RDY) India $12.261B 19.39
Aspen Pharmacare (APNHY) South Africa $5.328B 0.00
BridgeBio Pharma (BBIO) United States $4.794B 0.00
Bausch Health Cos (BHC) Canada $3.201B 2.50
Amphastar Pharmaceuticals (AMPH) United States $2.016B 13.80
Supernus Pharmaceuticals (SUPN) United States $1.655B 0.00
Generation Bio (GBIO) United States $0.188B 0.00
Personalis (PSNL) United States $0.074B 0.00
Assembly Biosciences (ASMB) United States $0.068B 0.00
Acasti Pharma (ACST) Canada $0.026B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00